Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/3/2025

Diagnostic and Management Approach for Systemic Vasculitis

Introduction to Systemic Vasculitis

  • Early diagnosis and aggressive treatment of systemic vasculitis are essential to reduce morbidity and mortality, with a diagnostic approach based on clinical presentation, laboratory testing, and often tissue biopsy for definitive diagnosis, as recommended by the European League Against Rheumatism 1, 2

Diagnostic Approach

  • Antineutrophil cytoplasmic antibodies (ANCA) testing is highly specific for small-vessel vasculitides, with anti-PR3 ANCA (c-ANCA) associated with Wegener's granulomatosis and anti-MPO ANCA (p-ANCA) associated with microscopic polyangiitis, according to the American College of Rheumatology 1
  • The European Vasculitis Study Group (EUVAS) classification includes localized, early systemic, generalized, and severe renal disease categories, which can guide treatment decisions 1

Disease Classification

  • Small vessel vasculitis includes ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis), as defined by the International Chapel Hill Consensus Conference 1

Management Approach

  • Treatment should be guided by disease severity, organ involvement, and patient factors, with mortality in vasculitis ranging from 0-25% at 1 year depending on disease severity, as reported by the European League Against Rheumatism 1
  • High-dose corticosteroids (methylprednisolone 1-2 mg/kg/day) are recommended as initial therapy for severe or life-threatening disease, according to the American College of Rheumatology 4
  • Cyclophosphamide is recommended for induction therapy in severe cases, as suggested by the European Vasculitis Study Group 4

Special Considerations

  • Renal involvement significantly impacts prognosis, with advanced renal involvement being the strongest predictor of mortality, as reported by the National Kidney Foundation 1
  • Drug-induced vasculitis should be evaluated and excluded, as recommended by the American College of Rheumatology 1